CRIMSON Study

Research study decision-making multiple sclerosis treatment funded @mssocietyuk PI @ana__manzano from @SSPLeeds and @thespleeds recruiting @LTHTrust

[Ieva Eskytė @ieva_eskyte]

The great thing about the @2016_Crimson is that people with #MS have been involved in the project from the very first stages and were active partners throughout the process

[CRIMSON Study @2016_Crimson]

What a great day! We met with people with MS and we gave them a red pen 🖊 to go over our brochure. They liked lots of things, they changed lots of things. We learned, we listened, and we laughed a lot... This is how people involvement in research looks like 👇🏾👇🏾@mssocietyuk

[CRIMSON Study @2016_Crimson]

@DJS_KBO @DrWBRO Thanks!So sorry you can’t make it! We may run another one in March but it is likely to be in the North

[CRIMSON Study @2016_Crimson]

Still spaces available for this event! Come and join our researchers 👇🏾👇🏾👇🏾👇🏾����🏾👇🏾👇🏾👇🏾👇🏾👇🏾

[George Pepper @gpeps]

On the red eye to London for the second @shiftms strategy day of 2019. Today's focus: sustainable income. What a first day for @SophieDiMauro - the new https://t.co/7bbrc9IQAS digital marketing manager

[CRIMSON Study @2016_Crimson]

Do you want to get involved in research? Next Thursday we are running a workshop in London to talk about our study. Join us! https://t.co/egYSVTFlfu

[CRIMSON Study @2016_Crimson]

Next Thursday (14thFeb), our research team @ana__manzano are running a workshop in London to get people’s with MS views on our first decision aids drafts. Book here if you have Relapsing MS and would like to help us (booking password:CRIMSON) 👉🏾👉🏾https://t.co/FvPczI2p00

[CRIMSON Study @2016_Crimson]

Next Thursday (14thFeb), our research team @ana__manzano are running a workshop in London to get people’s with MS views on our first decision aids drafts. Book here if you have Relapsing MS and would like to help us (booking password:CRIMSON) 👉🏾👉🏾https://t.co/FvPczI2p00

[CRIMSON Study @2016_Crimson]

Next Thursday (14thFeb), our research team @ana__manzano are running a workshop in London to get people’s with MS views on our first decision aids drafts. Book here if you have Relapsing MS and would like to help us (booking password:CRIMSON) 👉🏾👉🏾https://t.co/FvPczI2p00

[UKMSRegister @UKMSRegister]

With an ever increasing emphasis on patient involvement in medical research, the UK MS Register is becoming a recognised tool in MS research… https://t.co/RF8hGvXmZz

#MS #Multiplesclerosis @MSIntFederation @mssocietyuk @AMRC @SwanseaUni @SwanseaMedicine

[MSBase Registry @MSBase_Registry]

MSBase published in @JAMANeuro! 'Potential Benefits of Early Aggressive Treatment in MS' W.Brown and T.Kalincik showed even with relatively low efficacy drugs there is a 30% reduction in developing SPMS. Well done to all contributing MSBase investigators! https://t.co/kLlY28mb3D

[MS Society Stratford @stratford_ms]

Cannabis and MS https://t.co/bGwuXsm9jo

[Shift.ms @shiftms]

Facing an MS diagnosis is not something we get to choose.

Facing an MS diagnosis alone is.

If you're feeling lost, why not request a buddy and get partnered up with someone who's been on your shoes before and walked away stronger: https://t.co/1z3VcWtDSM

[MS Society NI @mssocietyNI]

MS-STAT2 trial update for secondary progressive MS with Dr Jeremy Chataway @UCLIoN

Tuesday 12th February at the MS Resource Centre. Join us from 2.30pm sharp to hear the latest updates in #MS research and find out how you can get involved in this trial. https://t.co/dymfFtokaI

[Dr. Brandon Beaber @Brandon_Beaber]

A study published in JAMA suggests that initial treatment of MS with Gilenya (fingolimod), Tysabri (natalizumab), or Lemtrada (alemtuzumab) is associated with a lower risk of conversion to secondary progressive multiple sclerosis (SPMS) https://t.co/P08irxbdAq

[Ieva Eskytė @ieva_eskyte]

Happy to announce that my book Disability and Shopping: Customers, Markets and the State is out!
https://t.co/Gbrr92gD87
#disability #customers #accessibility #market

[Cambridge Clinical MS Research @CambridgeMS1]

Very proud of this paper from our own Will Brown and the MSBase team: early aggressive treatment of RRMS delays onset of secondary progression https://t.co/8GXZUsvQTO

[Glyn Elwyn MD MSc PhD @glynelwyn]

Review, meta-analysis, and synthesis - the impact of using brief decision support tools in clinical encounters.

https://t.co/MC2eUf8UBz

[UKMSRegister @UKMSRegister]

The latest edition of our #MS Register #newsletter should be in your email inbox today. If you're registered with us and have not consented to received the newsletter but would like to, please get in touch with us. #SeasonsGreetings